Drug Profile
Research programme: ion channel targeted therapeutics - Evotec SE/Ono Pharmaceutical
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Ono Pharmaceutical
- Developer Evotec SE; Ono Pharmaceutical
- Class Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; CNS disorders; Genitourinary disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Germany (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in Germany (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Genitourinary-disorders in Germany (PO)